Concerns About Methods Used in Modeling Study of Risk-Stratified Screening for Breast Cancer-Reference-Cited by-同舟云学术

Concerns About Methods Used in Modeling Study of Risk-Stratified Screening for Breast Cancer

Published:2022-03-01 Issue:3 Volume:8 Page:483
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Pashayan Nora¹,Pharoah Paul D. P.²

Affiliation:

1. Department of Applied Health Research, University College London, London, United Kingdom

2. Departments of Oncology and Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Worts Causeway, Cambridge, United Kingdom

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2788328/jamaoncology_pashayan_2022_le_210050_1647458372.20737.pdf

Reference6 articles.

1. Concerns about methods used in modeling study of risk-stratified screening for breast cancer.;Vickers;JAMA Oncol,2021

2. Cost-effectiveness and benefit-to-harm ratio of risk-stratified screening for breast cancer: a life-table model.;Pashayan;JAMA Oncol,2018

3. The WISDOM Study: breaking the deadlock in the breast cancer screening debate.;Esserman;NPJ Breast Cancer,2017

4. Errors in the calculation used to estimate number of overdiagnoses in study of risk-stratified screening for breast cancer.;JAMA Oncol

5. US National Library of Medicine. My Personalized Breast Screening (MyPeBS). Accessed October 15, 2021. https://clinicaltrials.gov/ct2/show/NCT03672331

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. IFI30 as a key regulator of PDL1 immunotherapy prognosis in breast cancer;International Immunopharmacology;2024-05

2. Bioinformatics Method Was Used to Analyze the Highly Expressed Gene FAM83A of Breast Cancer in Young Women;Applied Bionics and Biomechanics;2022-03-29

3. Errors in the Calculation Used to Estimate Number of Overdiagnoses in Study of Risk-Stratified Screening for Breast Cancer;JAMA Oncology;2022-03-01

4. Changes Reflecting Corrections to Related Article;JAMA Oncology;2022-03-01